Real-Life Comparative Effectiveness of IL-23 Inhibitors in the Treatment of Moderate to Severe Psoriasis: A Multicenter Experience-Reference-Cited by-同舟云学术

Real-Life Comparative Effectiveness of IL-23 Inhibitors in the Treatment of Moderate to Severe Psoriasis: A Multicenter Experience

Published:2024-07-31 Issue: Volume: Page:e2024179
ISSN:2160-9381
Container-title:Dermatology Practical & Conceptual
language:
Short-container-title:

Author:

Borghi Alessandro¹,Odorici Giulia¹,Bardazzi Federico²,Filippi Federica²,Bigi Laura³,Lasagni Claudia³,Manfredini Marco³,Di Lernia Vito⁴,Peccerillo Francesca⁴,Conti Andrea⁵,Tiberio Rossana⁵,Satolli Francesca⁶,Fantini Carolina⁶,Rovesti Miriam⁷,Gasperini Massimo⁷,Tabanelli Michela⁸,D'Adamio Simone⁸,Flacco Maria Elena⁹,Corazza Monica¹

Affiliation:

1. Section of Dermatology and Infectious Diseases, Department of Medical Sciences, University of Ferrara, Ferrara, Italy

2. Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy

3. Dermatology Unit, Department of Surgical, Medical, Dental and Morphological Sciences Related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy

4. Dermatology Unit, Arcispedale Santa Maria Nuova, Azienda Usl-IRCCS di Reggio Emilia, Reggio Emilia, Italy

5. Dermatology Unit, Infermi Hospital, Rimini, AUSL Romagna, Italy

6. Section of Dermatology, Department of Medicine and Surgery, University of Parma, Parma, Italy

7. Dermatologic Unit, Ospedale “Guglielmo da Saliceto” di Piacenza PC, Italy

8. UOC Dermatology of Ravenna, Lugo and Faenza, Italy

9. Department of Environmental and Prevention Sciences, University of Ferrara, Ferrara, Italy

Publisher

Mattioli1885

Reference6 articles.

1. Mastorino L, Dapavo P, Susca S, Cariti C, Siliquini N, Verrone A, Stroppiana E, Ortoncelli M, Quaglino P, Ribero S. Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment. J Dtsch Dermatol Ges. 2023 Nov

2. Megna M, Tommasino N, Potestio L, et al. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. J Dermatolog Treat2022;33:2813-2820

3. Reich K, Gordon KB, Strober B, et al. Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance. J Eur Acad Dermatol Venereol2022;36:2393-2400.

4. Elgaard CDB, Iversen L, Hjuler KF. Guselkumab, Tildrakizumab and Risankizumab in Real-World Setting: Drug Survival and Effectiveness in the Treatment of Psoriasis and Psoriatic Arthritis. J Dermatolog Treat2022 6:1-24.

5. Ruggiero A, Fabbrocini G, Cinelli E, et al. Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study. Dermatol Ther.2022;35:e15214.